Mga Batayang Estadistika
| CIK | 1819133 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Tango Therapeutics, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 21, 2025 TANGO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39485 47-2452488 (State or other jurisdiction of incorporation) (Commissio |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q i113.ROC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39485 T |
|
| August 5, 2025 |
Tango Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights – First patient dosed in combination trial of TNG462 and Revolution Medicines RAS(ON) inhibitors – – First patient dosed in Phase 1/2 trial with TNG456, a brain-penetrant MTA-cooperative PRMT5 inhibitor in development for glioblastoma – BOSTON, August 5, 2025 (GLOBE NEWSWIRE) - Tango Therapeutics, Inc. |
|
| August 5, 2025 |
Non-Employee Director Compensation Policy Tango Therapeutics, Inc. AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Non-Employee Director Compensation Policy (the “Policy”) of Tango Therapeutics, Inc. (the “Company”) is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or officers of the Company or its |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGEACT OF 1934 Date of Report (Date of earliest event reported): August 5, 2025 TANGO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39485 85-1195036 (State or other jurisdiction of incorporation) (Commission |
|
| August 5, 2025 |
Confidential CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. |
|
| June 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 5, 2025 TANGO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39485 47-2452488 (State or other jurisdiction of incorporation) (Commission F |
|
| June 6, 2025 |
EX-3.1 Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF TANGO THERAPEUTICS, INC. (Pursuant to Section 242 of the General Corporation Law of the State of Delaware) Tango Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows: 1. The Corporation was origin |
|
| May 19, 2025 |
CORRESP VIA EDGAR May 19, 2025 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N. |
|
| May 12, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGEACT OF 1934 Date of Report (Date of earliest event reported): May 12, 2025 TANGO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39485 85-1195036 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q i113.ROC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39485 |
|
| May 12, 2025 |
Form of Subordinated Indenture between Registrant and one or more trustees to be named EX-4.6 Exhibit 4.6 TANGO THERAPEUTICS, INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 202[•] Subordinated Debt Securities TABLE OF CONTENTS(1) Article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 Article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trust |
|
| May 12, 2025 |
Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights – Data update from ongoing TNG462 Phase 1/2 monotherapy trial expected 2H 2025 – – Combination trial of TNG462 + Revolution Medicines RAS(ON) inhibitors on track for enrollment 2Q 2025 – – Cash position of $217 million as of March 31, 2025; cash runway extended into 1Q 2027 - with reduction of preclinical spend – BOSTON, May 12, 2025 (GLOBE NEWSWIRE) - Tango Therapeutics, Inc. |
|
| May 12, 2025 |
As filed with the Securities and Exchange Commission on May 12, 2025 S-3 Table of Contents As filed with the Securities and Exchange Commission on May 12, 2025 Registration No. |
|
| May 12, 2025 |
Form of Senior Indenture between Registrant and one or more trustees to be named EX-4.5 Exhibit 4.5 TANGO THERAPEUTICS, INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 202[•] Senior Debt Securities TABLE OF CONTENTS1 Page Article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 Article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee’ |
|
| May 12, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Tango Therapeutics, Inc. |
|
| April 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e |
|
| April 22, 2025 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| April 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39485 TANGO THERAPEUT |
|
| February 27, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGEACT OF 1934 Date of Report (Date of earliest event reported): February 27, 2025 TANGO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39485 85-1195036 (State or other jurisdiction of incorporation) (Commissi |
|
| February 27, 2025 |
Tango Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Highlights – TNG462 granted Orphan Drug Designation for treatment of pancreatic cancer – – Investigational New Drug (IND) application for TNG456, a next-generation brain-penetrant MTA-cooperative PRMT5 inhibitor, cleared by FDA. |
|
| February 27, 2025 |
Insider Trading Policy of Tango Therapeutics, Inc. TANGO THERAPEUTICS, INC. Insider Trading POLICY This Insider Trading Policy (the “Insider Trading Policy”) is designed to prevent insider trading or the appearance of impropriety, to satisfy the obligations of Tango Therapeutics, Inc. and its subsidiaries (collectively, the “Company”) to reasonably supervise the activities of Company personnel, and to help Company personnel avoid the severe conseq |
|
| February 27, 2025 |
As filed with the Securities and Exchange Commission on February 27, 2025 As filed with the Securities and Exchange Commission on February 27, 2025 Registration No. |
|
| February 27, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Tango Therapeutics, Inc. |
|
| February 14, 2025 |
AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G EXHIBIT 99.1 AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G The undersigned agree to file jointly with the Securities and Exchange Commission (the “SEC”) any and all statements on Schedule 13D or Schedule 13G or Forms 3, 4 or 5(and any amendments or supplements thereto) required under section 13(d) and 16(a) of the Securities Exchange Act of 1934, as amended, in connection wi |
|
| January 13, 2025 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 13, 2025 TANGO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39485 85-1195036 (State or other jurisdiction of incorporation) (Commissi |
|
| January 13, 2025 |
Exhibit 99.1 The next wave of targeted therapies in oncology Corporate Overview January 2025 | 1 Disclaimer and Safe Harbor Statement Certain statements in this presentation may be considered forward-looking statements. Forward-looking statements generally relate to future events, Tango’s future financial and operating performance, goals, expectations, beliefs, development plans, as well as develo |
|
| November 20, 2024 |
EX-99.1 Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned, and any amendments thereto executed by the undersigned shall be filed on behalf of each of the undersigned without the necessity of filing any additional joint filing agreement. The undersigned acknowledge that each is responsible for the |
|
| November 20, 2024 |
TNGX / Tango Therapeutics, Inc. / TCG Crossover GP II, LLC - SC 13G Passive Investment SC 13G 1 d898449dsc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Tango Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 87583X109 (CUSIP Number) November 13, 2024 (Date of Event Which Requires Filing of This Statement) Check th |
|
| November 7, 2024 |
TNGX / Tango Therapeutics, Inc. / Boxer Capital Management, LLC Activist Investment SC 13D/A 1 ff409551813da-boxertango.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (RULE 13D - 101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(a) (Amendment No. 6)* Tango Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 87583X1 |
|
| November 6, 2024 |
Tango Therapeutics Reports Positive TNG462 Clinical Data and Provides Update on PRMT5 Development Program – TNG462 demonstrated durable clinical activity across multiple tumor types, including non-small cell lung cancer (NSCLC) and pancreatic cancer, in ongoing phase 1/2 clinical trial, moving into full development – – Multiple TNG462 combination studies planned in 1H 2025 – – Clinical collaborati |
|
| November 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGEACT OF 1934 Date of Report (Date of earliest event reported): November 6, 2024 TANGO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39485 85-1195036 (State or other jurisdiction of incorporation) (Commissio |
|
| November 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q 113.ROC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-394 |
|
| November 6, 2024 |
Tango Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights – Positive TNG462 clinical activity across multiple tumor types in the phase 1/2 clinical trial, program moving into full development with multiple combination studies – – Clinical collaboration established with Revolution Medicines to evaluate TNG462 in combination with RAS(ON) multi- and G12D-selective inhibitors – – Next-generation brain-penetrant MTA-cooperative PRMT5 inhibitor, TNG456, planned to enter the clinic in 1H 2025 – – Strong cash position of $293 million as of September 30, 2024, with cash runway into 3Q 2026 to prioritize resourcing of TNG462 and TNG456 clinical trials – BOSTON, Mass. |
|
| October 28, 2024 |
TNGX / Tango Therapeutics, Inc. / Boxer Capital Management, LLC Activist Investment SC 13D/A 1 ff404326213da5-boxertango.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (RULE 13D - 101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(a) (Amendment No. 5)* Tango Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 87583X |
|
| October 15, 2024 |
TNGX / Tango Therapeutics, Inc. / Boxer Asset Management Inc. Activist Investment SC 13D/A 1 ff399376813da4-tango.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (RULE 13D - 101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(a) (Amendment No. 4)* Tango Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 87583X109 ( |
|
| October 15, 2024 |
TNGX / Tango Therapeutics, Inc. / Boxer Capital, LLC Activist Investment SC 13D/A 1 ff399644213da4-tangoboxcap.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (RULE 13D - 101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(a) (Amendment No. 4)* Tango Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 87583 |
|
| September 4, 2024 |
TNGX / Tango Therapeutics, Inc. / Third Rock Ventures IV, L.P. - SC 13D/A Activist Investment SC 13D/A 1 d857596dsc13da.htm SC 13D/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Tango Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value (Class of Securities) 87583X109 (CUSIP Number) Kevin Gillis Third Rock Ventures, LLC 201 Brookline Ave, Suite 1401, Boston, MA 02215 (617) 585-2000 (Name, A |
|
| August 7, 2024 |
Non-Employee Director Compensation Policy. TANGO therapeutics, INC. AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Non-Employee Director Compensation Policy (the “Policy”) of Tango Therapeutics, Inc. (the “Company”) is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or officers of the Company or its |
|
| August 7, 2024 |
Tango Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights – Dose expansion ongoing in TNG908 and TNG462 phase 1/2 clinical trials; comprehensive clinical data update for the PRMT5 program expected in 2H 2024 – – Patient enrollment is ongoing in TNG260 phase 1/2 clinical trial – – Strong cash position of $322 million as of June 30, 2024; cash runway into 2027 expected to fund clinical programs through proof-of-concept – BOSTON, Mass. |
|
| August 7, 2024 |
Second Amended and Restated Certificate of Incorporation of Tango Therapeutics, Inc., as amended SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF BCTG ACQUISITION CORP. |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q 113.ROC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39485 TA |
|
| August 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGEACT OF 1934 Date of Report (Date of earliest event reported): August 7, 2024 TANGO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39485 85-1195036 (State or other jurisdiction of incorporation) (Commission |
|
| June 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 5, 2024 TANGO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39485 85-1195036 (State or other jurisdiction of incorporation) (Commission F |
|
| June 6, 2024 |
Certificate of Amendment of the Restated Certificate of Incorporation of Tango Therapeutics, Inc. Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF TANGO THERAPEUTICS, INC. (Pursuant to Section 242 of the General Corporation Law of the State of Delaware) Tango Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows: 1. The Corporation was originally in |
|
| May 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 23, 2024 TANGO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39485 47-2452488 (State or other jurisdiction of incorporation) (Commission F |
|
| May 23, 2024 |
EX-99.1 2 d823505dex991.htm EX-99.1 Exhibit 99.1 Tango Therapeutics Announces Discontinuation of TNG348 Program – The phase 1/2 clinical trial of TNG348, a USP1 inhibitor, is being terminated due to toxicity observed in the initial study cohorts – – Cash runway extended into 2027, PRMT5 and CoREST clinical programs remain on track – BOSTON, Mass. – May 23, 2024 – Tango Therapeutics, Inc. (NASDAQ: |
|
| May 8, 2024 |
Tango Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights – Dose expansion initiated in TNG908 phase 1/2 clinical trial – – Dose expansion expected to initiate in TNG462 phase 1/2 clinical trial in 2Q 2024 – – Clinical data expected in 2H 2024 from PRMT5 program – – Dose escalation ongoing in TNG260 and TNG348 clinical-stage precision oncology programs – – Strong cash position of $344 million as of March 31, 2024; cash runway into late 2026 expected to fund all clinical programs through proof-of-concept – BOSTON, Mass. |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q 113.ROC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39485 T |
|
| May 8, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGEACT OF 1934 Date of Report (Date of earliest event reported): May 8, 2024 TANGO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39485 85-1195036 (State or other jurisdiction of incorporation) (Commission Fil |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 8, 2024 |
TNGX / Tango Therapeutics, Inc. / Southpoint Capital Advisors LP - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Tango Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 87583X109 (CUSIP Number) April 8, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the r |
|
| March 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39485 TANGO THERAPEUT |
|
| March 18, 2024 |
Tango Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Highlights – Dose escalation ongoing in four clinical-stage precision oncology programs; TNG908 phase 1/2 clinical data expected in 2024 – – First patient dosed in phase 1/2 clinical trial of TNG348 in patients with BRCA1/2-mutant and other HRD+ cancers – – FDA Orphan Drug Designation granted for TNG462 for the treatment of soft tissue sarcomas – – Strong cash position of $337 million as of December 31, 2023, combined with $42 million in proceeds from ATM in January 2024; cash runway into late 2026 expected to fund all clinical programs through proof-of-concept – BOSTON, Mass. |
|
| March 18, 2024 |
As filed with the Securities and Exchange Commission on March 18, 2024 As filed with the Securities and Exchange Commission on March 18, 2024 Registration No. |
|
| March 18, 2024 |
List of subsidiaries of Tango Therapeutics, Inc. Exhibit 21.1 Exhibit 21.1 List of Subsidiaries Tango Therapeutics Sub, Inc., a Delaware corporation Tango Securities Corporation, a Massachusetts corporation |
|
| March 18, 2024 |
Tango Therapeutics, Inc. Compensation Recovery Policy TANGO THERAPEUTICS, INC. COMPENSATION RECOVERY POLICY Adopted as of September 14, 2023 Tango Therapeutics, Inc., a Delaware corporation (the “Company”), has adopted a Compensation Recovery Policy (this “Policy”) as described below. 1. Overview The Policy sets forth the circumstances and procedures under which the Company shall recover Erroneously Awarded Compensation from Covered Persons (as defin |
|
| March 18, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Tango Therapeutics, Inc. |
|
| March 18, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGEACT OF 1934 Date of Report (Date of earliest event reported): March 18, 2024 TANGO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39485 85-1195036 (State or other jurisdiction of incorporation) (Commission |
|
| February 14, 2024 |
TNGX / Tango Therapeutics, Inc. / Southpoint Capital Advisors LP - SC 13G/A Passive Investment SC 13G/A 1 d772348dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Tango Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 87583X109 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the |
|
| February 13, 2024 |
TNGX / Tango Therapeutics, Inc. / GILEAD SCIENCES INC - SC 13G/A Passive Investment SC 13G/A 1 d756953dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* TANGO THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 87583X109 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the ap |
|
| February 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 7, 2024 TANGO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39485 47-2452488 (State or other jurisdiction of incorporation) (Commissi |
|
| November 8, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGEACT OF 1934 Date of Report (Date of earliest event reported): November 8, 2023 TANGO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39485 85-1195036 (State or other jurisdiction of incorporation) (Commissio |
|
| November 8, 2023 |
Tango Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Highlights – Dose escalation ongoing in phase 1/2 trials of lead PRMT5 inhibitors TNG908 and TNG462; additional TNG908 clinical data expected 2024 – – Dose escalation ongoing in phase 1/2 trial of CoREST inhibitor TNG260 and pembrolizumab in patients with STK11 mutant solid tumors – – FDA Fast Track designation granted for TNG348, a novel USP1 inhibitor, for the treatment of BRCA1/2-mutant breast and ovarian cancer; phase 1/2 clinical trial initiation expected 1H 2024 – – Kanishka Pothula, partner at Nextech Ventures, appointed to Board of Directors, replacing Reid Huber, Ph. |
|
| November 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ROC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39485 TANGO THERAPEUTICS, INC. |
|
| October 18, 2023 |
TNGX / Tango Therapeutics Inc / BCTG Holdings, LLC Activist Investment SC 13D/A 1 ff260961713da3-tango.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-101) Under the Securities Exchange Act of 1934 (Amendment No. 3)* Tango Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 87583X109 (CUSIP Number) Josh La Grange Fried, Frank, Harris, Shriver & Jacobson LLP 801 17th Street, NW, |
|
| October 16, 2023 |
TNGX / Tango Therapeutics Inc / EcoR1 Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Tango Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 87583X109 (CUSIP Number) October 13, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| September 21, 2023 |
TNGX / Tango Therapeutics Inc / EcoR1 Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Tango Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 87583X109 (CUSIP Number) September 11, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| September 7, 2023 |
VIA EDGAR September 7, 2023 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N. |
|
| September 1, 2023 |
As filed with the Securities and Exchange Commission on September 1, 2023 Form S-3 Table of Contents As filed with the Securities and Exchange Commission on September 1, 2023 Registration No. |
|
| September 1, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Tango Therapeutics, Inc. |
|
| August 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGEACT OF 1934 Date of Report (Date of earliest event reported): August 28, 2023 TANGO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39485 85-1195036 (State or other jurisdiction of incorporation) (Commission |
|
| August 21, 2023 |
TNGX / Tango Therapeutics Inc / Nextech Crossover I GP S.a r.l. - SC 13G Passive Investment SC 13G 1 tm2324134d1sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Tango Therapeutics, Inc. (Name of Issuer) Common stock, $0.001 par value per share (Title of Class of Securities) 87583X109 (CUSIP Number) August 11, 2023 (Date of Event Which Requires Filing of this Statement) Check t |
|
| August 16, 2023 |
TNGX / Tango Therapeutics Inc / BCTG Holdings, LLC Activist Investment SC 13D/A 1 ff239281213da2-tango.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-101) Under the Securities Exchange Act of 1934 (Amendment No. 2)* Tango Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 87583X109 (CUSIP Number) Josh La Grange Fried, Frank, Harris, Shriver & Jacobson LLP 801 17th Street, NW, |
|
| August 10, 2023 |
Tango Therapeutics Announces $80 million Private Placement Financing EX-99.1 Exhibit 99.1 Tango Therapeutics Announces $80 million Private Placement Financing BOSTON, Mass. – August 10, 2023 – Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, has agreed to sell approximately 15.5 million shares of its common stock (“Common Stock”) (or pre-funded |
|
| August 10, 2023 |
EX-10.1 Exhibit 10.1 Execution Version TANGO THERAPEUTICS, INC. SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (the “Agreement”) is made as of August 10, 2023 (the “Effective Date”), by and among Tango Therapeutics, Inc., a Delaware corporation (the “Company”), and the purchasers whose names and addresses are set forth on the signature pages hereof (each, a “Purchaser” and, colle |
|
| August 10, 2023 |
EX-4.1 Exhibit 4.1 THESE SECURITIES REPRESENTED HEREBY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE BUT HAVE BEEN OR WILL BE ISSUED IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND, ACCORDINGLY, MAY NOT BE TRANSFERRED UNLES |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 10, 2023 TANGO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39485 85-1195036 (State or other jurisdiction of incorporation) (Commissio |
|
| August 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGEACT OF 1934 Date of Report (Date of earliest event reported): August 3, 2023 TANGO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39485 85-1195036 (State or other jurisdiction of incorporation) (Commission |
|
| August 7, 2023 |
TANGO therapeutics, INC. AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Non-Employee Director Compensation Policy (the “Policy”) of Tango Therapeutics, Inc. (the “Company”) is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or officers of the Company or its |
|
| August 7, 2023 |
Tango Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Highlights – First patient dosed in phase 1/2 trial of TNG462, a next-generation PRMT5 inhibitor for the treatment of MTAP-deleted tumors – – Dose escalation ongoing in phase 1/2 trial of TNG908, a novel brain-penetrant PRMT5 inhibitor for the treatment of MTAP-deleted tumors – – First patient dosed in phase 1/2 trial of TNG260, a first-in-class CoREST complex inhibitor, with pembrolizumab for the treatment STK11-mutant cancers – – Alan Huang, Ph. |
|
| August 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ROC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39485 TANGO THERAPEUTICS, INC. |
|
| June 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 6, 2023 TANGO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39485 85-1195036 (State or other jurisdiction of incorporation) (Commission F |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGEACT OF 1934 Date of Report (Date of earliest event reported): May 9, 2023 TANGO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39485 85-1195036 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ROC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39485 TANGO THERAPEUTICS, INC. |
|
| May 9, 2023 |
Tango Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Highlights – Dose escalation update from ongoing TNG908 clinical trial confirms proof-of-mechanism for MTA-cooperative tumor-selective PRMT5 inhibition in MTAP-deleted cancers – – FDA clears IND application for TNG260, a first-in-class CoREST complex inhibitor for the treatment of STK11-mutant cancers – – Fast Track designation granted by FDA for TNG260 + anti-PD-1 antibody for the treatment of patients with advanced NSCLC with STK11-loss of function mutations – – Strong cash position of $334 million expected to support advancing precision oncology pipeline into 2026 – BOSTON, Mass. |
|
| April 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| March 27, 2023 |
Tango Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Highlights – Fast Track Designation granted to TNG462, next-generation MTA-Cooperative PRMT5 inhibitor – – Adam Crystal, M. |
|
| March 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGEACT OF 1934 Date of Report (Date of earliest event reported): March 27, 2023 TANGO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39485 85-1195036 (State or other jurisdiction of incorporation) (Commission |
|
| March 27, 2023 |
Exhibit 4.2 DESCRIPTION OF REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following summary of certain provisions of Tango Therapeutics, Inc.’s (“Tango”, “we”, “our”) securities does not purport to be complete and is subject to the Second Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation” or “Charter”), the Am |
|
| March 27, 2023 |
List of subsidiaries of Tango Therapeutics, Inc. Exhibit 21.1 Exhibit 21.1 List of Subsidiaries Tango Therapeutics Sub, Inc., a Delaware corporation Tango Securities Corporation, a Massachusetts corporation |
|
| March 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHaANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39485 TANGO THERAPEU |
|
| February 28, 2023 |
EX-99.1 Exhibit 99.1 Tango Therapeutics Announces Appointment of Adam Crystal, M.D., Ph.D. as President of Research and Development BOSTON, Mass. – February 28, 2023 – Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced the appointment of Adam Crystal, M.D., Ph.D. |
|
| February 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 27, 2023 TANGO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39485 47-2452488 (State or other jurisdiction of incorporation) (Commiss |
|
| February 14, 2023 |
TNGX / Tango Therapeutics, Inc. / Casdin Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2023 |
TNGX / Tango Therapeutics, Inc. / Cormorant Asset Management, LP Passive Investment SC 13G/A 1 schedule13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Tango Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 87583X109 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate th |
|
| February 7, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Tango Therapeutics, Inc. |
|
| February 7, 2023 |
As filed with the Securities and Exchange Commission on February 7, 2023 S-8 As filed with the Securities and Exchange Commission on February 7, 2023 Registration No. |
|
| February 7, 2023 |
EX-99.1 Exhibit 99.1 TANGO THERAPEUTICS, INC. 2023 INDUCEMENT PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Tango Therapeutics, Inc. 2023 Inducement Plan (as amended from time to time, the “Plan”). The purpose of the Plan is to enable Tango Therapeutics, Inc. (the “Company”) to grant equity awards to induce highly-qualified prospective officers and employees |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGEACT OF 1934 Date of Report (Date of earliest event reported): November 10, 2022 TANGO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39485 85-1195036 (State or other jurisdiction of incorporation) (Commissi |
|
| November 10, 2022 |
Tango Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Highlights ? Clinical Trial Application (CTA) for TNG908, an MTA-cooperative PRMT5 inhibitor, approved by the National Agency for the Safety of Medicines (ANSM) in France ? ? TNG260 disclosed as a first-in-class CoREST complex inhibitor for treatment of STK11-mutant cancers ? ? TNG348 declared as a USP1 inhibitor development candidate for treatment of BRCA1/2 mutant cancers ? ? Aaron Weitzman, M. |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q usROC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39485 TANGO THERAPEUTICS, INC. |
|
| September 21, 2022 |
As filed with the Securities and Exchange Commission on September 21, 2022 Table of Contents As filed with the Securities and Exchange Commission on September 21, 2022 Registration Statement No. |
|
| September 8, 2022 |
VIA EDGAR September 8, 2022 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N. |
|
| September 1, 2022 |
Form of Subordinated Indenture between Registrant and one or more trustees to be named Exhibit 4.6 TANGO THERAPEUTICS, INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?], 202[?] Subordinated Debt Securities TABLE OF CONTENTS(1) Article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 Article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee?s Ce |
|
| September 1, 2022 |
Exhibit 1.2 OPEN MARKET SALE AGREEMENTSM September 1, 2022 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Tango Therapeutics, Inc., a Delaware corporation (the ?Company?), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the ?Agent?), shares of the Company?s comm |
|
| September 1, 2022 |
Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-3 (Form Type) Tango Therapeutics, Inc. |
|
| September 1, 2022 |
Form of Senior Indenture between Registrant and one or more trustees to be named Exhibit 4.5 TANGO THERAPEUTICS, INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?], 202[?] Senior Debt Securities TABLE OF CONTENTS1 Page Article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms. 1 Article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities. 4 Section 2.02 Form of Securities and Trustee?s Cer |
|
| September 1, 2022 |
As filed with the Securities and Exchange Commission on September 1, 2022 Table of Contents As filed with the Securities and Exchange Commission on September 1, 2022 Registration No. |
|
| August 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGEACT OF 1934 Date of Report (Date of earliest event reported): August 10, 2022 TANGO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39485 85-1195036 (State or other jurisdiction of incorporation) (Commission |
|
| August 10, 2022 |
Tango Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Highlights ? Patients with MTAP-deleted solid tumors being actively enrolled in ongoing Phase 1/2 trial of TNG908, an MTA-cooperative PRMT5 inhibitor ? ? Received Orphan Drug Designation in US for the treatment of malignant peripheral nerve sheath tumors with TNG908 ? CAMBRIDGE, Mass. |
|
| August 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q usROC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39485 TANGO THERAPEUTICS, INC. |
|
| August 10, 2022 |
Up to 68,175,412 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-259448 Prospectus Supplement No. 3 (to Prospectus dated March 28, 2022) Up to 68,175,412 Shares of Common Stock This prospectus supplement updates and supplements the prospectus dated March 28, 2022 (the ?Prospectus?), which forms a part of our Registration Statement on Form S-1, as amended (Registration No. 333-259448). This prospectus supplem |
|
| July 11, 2022 |
TNGX / Tango Therapeutics, Inc. / Southpoint Capital Advisors LP - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Tango Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 87583X109 (CUSIP Number) June 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule p |
|
| June 10, 2022 |
Up to 68,175,412 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-259448 Prospectus Supplement No. 2 (to Prospectus dated March 28, 2022) Up to 68,175,412 Shares of Common Stock This prospectus supplement updates and supplements the prospectus dated March 28, 2022 (the ?Prospectus?), which forms a part of our Registration Statement on Form S-1 (333-259448). This prospectus supplement is being filed to update |
|
| June 10, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGECOMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGEACT OF 1934 Date of Report (Date of earliest event reported): June 8, 2022 TANGO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39485 85-1195036 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 11, 2022 |
Up to 68,175,412 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-259448 Prospectus Supplement No. 1 (to Prospectus dated March 28, 2022) Up to 68,175,412 Shares of Common Stock This prospectus supplement updates and supplements the prospectus dated March 28, 2022 (the ?Prospectus?), which forms a part of our Registration Statement on Form S-1, as amended (Registration No. 333-259448). This prospectus supplem |
|
| May 11, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGECOMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGEACT OF 1934 Date of Report (Date of earliest event reported): May 11, 2022 TANGO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39485 85-1195036 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 11, 2022 |
Non-Employee Director Compensation Policy TANGO therapeutics, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Non-Employee Director Compensation Policy (the ?Policy?) of Tango Therapeutics, Inc. (the ?Company?) is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or officers of the Company or its subsidiaries (?Outsi |
|
| May 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ROC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39485 TANGO THERAPEUTICS, INC. |
|
| May 11, 2022 |
Tango Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Highlights – Phase 1/2 trial of TNG908, a synthetic lethal PRMT5 inhibitor, for the treatment of MTAP-deleted solid tumors open for enrollment – – Declared TNG462 as a development candidate - a next-generation PRMT5 inhibitor for MTAP-deleted solid tumors – – Declared TNG260 as a development candidate - an inhibitor of an undisclosed synthetic lethal target that reverses the immune evasion effect of STK11 loss-of-function mutations – – Strong cash position of $450 million expected to support advancing discovery and clinical pipeline into second half of 2024 – CAMBRIDGE, Mass. |
|
| April 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| March 28, 2022 |
Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential. |
|
| March 28, 2022 |
Table of Contents As filed with the Securities and Exchange Commission on March 28, 2022 Registration Statement No. |
|
| March 28, 2022 |
Exhibit 4.2 DESCRIPTION OF REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following summary of certain provisions of Tango Therapeutics, Inc.?s (?Tango?, ?we?, ?our?) securities does not purport to be complete and is subject to the Second Amended and Restated Certificate of Incorporation (the ?Certificate of Incorporation? or ?Charter?), the Am |
|
| March 28, 2022 |
Exhibit 99.1 Tango Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights - TNG908 receives Fast Track designation, expects Phase 1/2 trial to start in 2Q 2022 - Pipeline programs progressing throughout 2022 - - Strong cash position of $485 million expected to support operations into second half of 2024 - CAMBRIDGE, Mass. ? March 28, 2022 ? Tango |
|
| March 28, 2022 |
As filed with the Securities and Exchange Commission on March 28, 2022 As filed with the Securities and Exchange Commission on March 28, 2022 Registration No. |
|
| March 28, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 28, 2022 TANGO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39485 85-1195036 (State or other jurisdiction of incorporation) (Commission |
|
| March 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39485 TANGO THERAPEUT |
|
| March 28, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Tango Therapeutics, Inc. |
|
| February 14, 2022 |
Exhibit 99.1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of February 14, 2022, is by and between Cormorant Asset Management, LP and Bihua Chen (collectively, the ?Filers?). Each of the Filers may be required to file with the United States Securities and Exchange Commission a statement on Schedule 13D and/or 13G with respect to shares of Common Stock of Tango Therapeutics, Inc. ben |
|
| February 14, 2022 |
TNGX / Tango Therapeutics, Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Tango Therapeutics, Inc. (f/k/a BCTG Acquisition Corp.) (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 87583X109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check th |
|
| February 14, 2022 |
TNGX / Tango Therapeutics, Inc. / Cormorant Asset Management, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Tango Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 87583X109 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| February 10, 2022 |
TNGX / Tango Therapeutics, Inc. / Southpoint Capital Advisors LP - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Tango Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 87583X109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate t |
|
| January 4, 2022 |
TNGX / Tango Therapeutics, Inc. / BCTG Holdings, LLC - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-101) Under the Securities Exchange Act of 1934 (Amendment No. |
|
| January 4, 2022 |
EXHIBIT 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D and any amendments to it with respect to Common Stock, $0. |
|
| November 9, 2021 |
Up to 68,034,602 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-259448 Prospectus Supplement No. 1 (to Prospectus dated October 7, 2021) Up to 68,034,602 Shares of Common Stock This prospectus supplement updates and supplements the prospectus dated October 7, 2021 (the ?Prospectus?), which forms a part of our Registration Statement on Form S-1 (333-259448). This prospectus supplement is being filed to updat |
|
| November 9, 2021 |
Exhibit 99.1 Tango Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Highlights ? Strong cash position of $504 million supports advancing discovery and clinical pipeline into second half of 2024 ? ? On track for IND filing in fourth quarter of 2021 for TNG908, an MTA-cooperative PRMT5 inhibitor that is synthetic lethal with MTAP deletion, for multiple cancers ? CAMBRI |
|
| November 9, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 9, 2021 TANGO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39485 47-2452488 (State or other jurisdiction of incorporation) (Commissi |
|
| November 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ROC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39485 TANGO THERAPEUTICS, INC. |
|
| October 14, 2021 |
As filed with the Securities and Exchange Commission on October 14, 2021 Registration No. |
|
| October 14, 2021 |
Exhibit 99.4 TANGO THERAPEUTICS, INC. 2017 STOCK OPTION AND GRANT PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Tango Therapeutics, Inc. 2017 Stock Option and Grant Plan (the ?Plan?). The purpose of the Plan is to encourage and enable the officers, employees, directors, Consultants and other key persons of Tango Therapeutics, Inc., a Delaware corporation (inc |
|
| October 14, 2021 |
Exhibit 4.2 AMENDED AND RESTATED BY-LAWS OF BCTG ACQUISITION CORP. (the ?Corporation?) ARTICLE I Stockholders SECTION 1. Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these By-laws as an ?Annual Meeting?) shall be held at the hour, date and place within or without the United States which is fixed by the Board of Directors, which time, date and place may |
|
| October 8, 2021 |
Up to 68,034,602 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-259448 PROSPECTUS Up to 68,034,602 Shares of Common Stock This prospectus relates to the offer and sale, from time to time, by the selling securityholders named in this prospectus, or the Selling Securityholders, or any of their pledgees, donees, assignees and successors-in-interest, or collectively, the permitted transferees, |
|
| September 29, 2021 |
Up to 68,175,412 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-259448 PROSPECTUS Up to 68,175,412 Shares of Common Stock This prospectus relates to the offer and sale, from time to time, by the selling securityholders named in this prospectus, or the Selling Securityholders, or any of their pledgees, donees, assignees and successors-in-interest, or collectively, the permitted transferees, |
|
| September 27, 2021 |
TANGO THERAPEUTICS, INC. 100 Binney St, Suite 700 Cambridge, MA 02142 TANGO THERAPEUTICS, INC. 100 Binney St, Suite 700 Cambridge, MA 02142 VIA EDGAR September 27, 2021 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Tim Buchmiller Re: Tango Therapeutics, Inc. Acceleration Request for Registration Statement on Form S-1 Filed September 10, 2021 File No. 333-259448 Dear Mr. Buchmiller: |
|
| September 10, 2021 |
TNGX / Tango Therapeutics, Inc. / GILEAD SCIENCES INC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* TANGO THERAPEUTICS, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 87583X109 (CUSIP Number) August 10, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua |
|
| September 10, 2021 |
Table of Contents As filed with the Securities and Exchange Commission on September 10 , 2021 Registration Statement No. |
|
| September 10, 2021 |
List of subsidiaries of Tango Therapeutics, Inc. Exhibit 21.1 SUBSIDIARIES Subsidiary Jurisdiction of Incorporation Tango Therapeutics Sub, Inc. Delaware Tango Securities Corporation Massachusetts |
|
| September 10, 2021 |
Exhibit 3.1 SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF BCTG ACQUISITION CORP. August 10, 2021 BCTG Acquisition Corp., a corporation organized and existing under the laws of the State of Delaware (the ?Corporation?), DOES HEREBY CERTIFY AS FOLLOWS: 1. The name of the Corporation is ?BCTG Acquisition Corp.? The original certificate of incorporation was filed with the Secretary of St |
|
| August 20, 2021 |
EX-99.1 2 d160102dex991.htm EX-99.1 EXHIBIT 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D and any amendments to it with respect to Common Stock, $0.001 par value per share, of Tango Therapeutics Inc. and further agree that |
|
| August 20, 2021 |
TNGX / Tango Therapeutics, Inc. / BCTG Holdings, LLC - SC 13D Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-101) Under the Securities Exchange Act of 1934 (Amendment No. |
|
| August 19, 2021 |
TNGX / Tango Therapeutics, Inc. / Third Rock Ventures IV, L.P. - SC 13D Activist Investment SC 13D SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Tango Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value (Class of Securities) 87583X109 (CUSIP Number) Kevin Gillis Third Rock Ventures, LLC 29 Newbury Street, 3rd Floor, Boston, MA 02116 (617) 585-2000 (Name, Address and Telephone Number of Per |
|
| August 19, 2021 |
Exhibit 99.1 CUSIP: 87583X109 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13D shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The undersigned acknowledge t |
|
| August 19, 2021 |
TNGX / Tango Therapeutics, Inc. / Casdin Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| August 13, 2021 |
Exhibit 10.8 TANGO THERAPEUTICS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Non-Employee Director Compensation Policy (the ?Policy?) of Tango Therapeutics, Inc. (the ?Company?) is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or officers of the Company or its subsidi |
|
| August 13, 2021 |
Exhibit 99.2 TANGO THERAPEUTICS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except share amounts) (Unaudited) June 30, 2021 December 31, 2020 Assets Current assets: Cash and cash equivalents $ 50,902 $ 28,381 Marketable securities 147,452 161,939 Accounts receivable 2,000 2,000 Prepaid expenses and other current assets 1,707 1,312 Total current assets 202,061 193,632 Property and eq |
|
| August 13, 2021 |
Exhibit 10.9 TANGO THERAPEUTICS, INC. FORM OF DIRECTOR INDEMNIFICATION AGREEMENT This Indemnification Agreement (?Agreement?) is made as of by and between Tango Therapeutics, Inc., a Delaware corporation (the ?Company?), and (?Indemnitee?). RECITALS WHEREAS, the Company desires to attract and retain the services of highly qualified individuals, such as Indemnitee, to serve the Company; WHEREAS, in |
|
| August 13, 2021 |
Exhibit 10.7 EMPLOYMENT AGREEMENT This Employment Agreement (?Agreement?) is made between Tango Therapeutics, Inc., a Delaware corporation (the ?Company?), and (the ?Executive?) and is effective as of the closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of April 13, 2021, by and among BCTG Acquisition Corp., BCTG Merger Sub Inc. and the Company (the ?Effective |
|
| August 13, 2021 |
Exhibit 10.2 AMENDED AND RESTATED REGISTRATION AND STOCKHOLDER RIGHTS AGREEMENT THIS AMENDED AND RESTATED REGISTRATION AND STOCKHOLDER RIGHTS AGREEMENT (this ?Agreement?) is entered into as of the 10th day of August, 2021, is made and entered into by and among. TANGO THERAPEUTICS, INC. a Delaware corporation (the ?Company?), and certain former stockholders of Tango Therapeutics, Inc. (?Old Tango?) |
|
| August 13, 2021 |
Exhibit 10.10 TANGO THERAPEUTICS, INC. FORM OF OFFICER INDEMNIFICATION AGREEMENT This Indemnification Agreement (?Agreement?) is made as of by and between Tango Therapeutics, Inc., a Delaware corporation (the ?Company?), and (?Indemnitee?). RECITALS WHEREAS, the Company desires to attract and retain the services of highly qualified individuals, such as Indemnitee, to serve the Company; WHEREAS, in |
|
| August 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 10, 2021 TANGO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39485 85-1195036 (State or other jurisdiction of incorporation) (Commissio |
|
| August 13, 2021 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Exhibit 99.4 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Capitalized terms used but not defined in this Exhibit 99.2 shall have the meanings ascribed to them in the Current Report on Form 8-K (the ?Form 8-K?) filed with the Securities and Exchange Commission (the ?SEC?) on August 13, 2021 and, if not defined in the Form 8-K, included in the Company?s effective proxy statement/pros |
|
| August 13, 2021 |
Exhibit 99.3 BCTG ACQUISITION CORP. CONDENSED CONSOLIDATED BALANCE SHEETS June 30, 2021 December 31, 2020 Assets: (Unaudited) Current assets: Cash $ 582,938 $ 1,314,085 Prepaid expenses 151,355 183,496 Total current assets 734,293 1,497,581 Investments held in Trust Account 166,815,023 166,815,235 Total Assets $ 167,549,316 $ 168,312,816 Liabilities and Stockholders? Equity: Current liabilities: A |
|
| August 13, 2021 |
Exhibit 10.4 TANGO THERAPEUTICS, INC. 2021 STOCK OPTION AND INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Tango Therapeutics, Inc. 2021 Stock Option and Incentive Plan (as amended from time to time, the ?Plan?). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultants of Tango Therapeutics, I |
|
| August 13, 2021 |
Exhibit 10.11 TANGO THERAPEUTICS, INC. SENIOR EXECUTIVE CASH INCENTIVE BONUS PLAN 1. Purpose This Senior Executive Cash Incentive Bonus Plan (the ?Incentive Plan?) is intended to provide an incentive for superior work and to motivate eligible executives of Tango Therapeutics, Inc. (the ?Company?) and its subsidiaries toward even higher achievement and business results, to tie their goals and inter |
|
| August 13, 2021 |
Exhibit 16.1 August 13, 2021 Office of the Chief Accountant Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Ladies and Gentlemen: We have read the statements of Tango Therapeutics, Inc. (formerly known as BCTG Acquisition Corp.) under Item 4.01(a) of its Form 8-K dated August 13, 2021. We agree with the statements concerning our Firm under Item 4.01(a), in which we were |
|
| August 13, 2021 |
Exhibit 10.6 TANGO THERAPEUTICS, INC. 2021 EMPLOYEE STOCK PURCHASE PLAN The purpose of the Tango Therapeutics, Inc. 2021 Employee Stock Purchase Plan (the ?Plan?) is to provide eligible employees of Tango Therapeutics, Inc. (the ?Company?) and each Designated Subsidiary (as defined in Section 11) with opportunities to purchase shares of the Company?s common stock, par value $0.001 per share (the ? |
|
| August 13, 2021 |
Exhibit 10.5 INCENTIVE STOCK OPTION AGREEMENT UNDER THE TANGO THERAPEUTICS, INC. 2021 STOCK OPTION AND INCENTIVE PLAN Name of Optionee: No. of Option Shares: Option Exercise Price per Share: $ [FMV on Grant Date (110% of FMV if a 10% owner)] Grant Date: Expiration Date: [No more than 10 years (5 years if a 10% owner)] Pursuant to the Tango Therapeutics, Inc. 2021 Stock Option and Incentive Plan, a |
|
| August 13, 2021 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS OF TANGO Exhibit 99.1 MANAGEMENT?S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS OF TANGO Management?s discussion and analysis of our financial condition and results of operations should be read together with Tango?s unaudited condensed consolidated financial statements and related notes appearing elsewhere in this Form 8-K and with Tango?s audited consolidated financial statemen |
|
| August 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to BCTG ACQUISITION CORP. (Exact name of registrant as spe |
|
| July 19, 2021 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-255354 PROXY STATEMENT FOR SPECIAL MEETING OF BCTG ACQUISITION CORP. AND PROSPECTUS FOR SHARES OF COMMON STOCK OF BCTG ACQUISITION CORP. BCTG Acquisition Corp. 12860 El Camino Real, Suite 300 San Diego, CA 92130 To the Stockholders of BCTG Acquisition Corp.: You are cordially invited to attend the Special Meeting of Stockholders (the ?Special M |
|
| July 16, 2021 |
Consent to Reference in Proxy Statement/Prospectus EX-99.6 9 ea144230ex99-6bctgacq.htm CONSENT OF MALTE PETERS TO BE NAMED AS A DIRECTOR Exhibit 99.6 July 14, 2021 Consent to Reference in Proxy Statement/Prospectus BCTG Acquisition Corp, Inc. (the “Company”) is filing a Registration Statement on Form S-4 (the “Registration Statement”) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”). I |
|
| July 16, 2021 |
EX-21.1 4 ea144230ex21-1bctgacq.htm LIST OF SUBSIDIARIES Exhibit 21.1 List of Subsidiaries BCTG Acquisition Corp. BCTG Merger Sub Inc., a Delaware corporation Tango Therapeutics, Inc. Tango Securities Corporation, a Massachusetts corporation |
|
| July 16, 2021 |
Consent to Reference in Proxy Statement/Prospectus EX-99.8 11 ea144230ex99-8bctgacq.htm CONSENT OF MACE ROTHENBERG TO BE NAMED AS A DIRECTOR Exhibit 99.8 July 14, 2021 Consent to Reference in Proxy Statement/Prospectus BCTG Acquisition Corp, Inc. (the “Company”) is filing a Registration Statement on Form S-4 (the “Registration Statement”) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act” |
|
| July 16, 2021 |
Consent to Reference in Proxy Statement/Prospectus EX-99.7 10 ea144230ex99-7bctgacq.htm CONSENT OF LESLEY CALHOUN TO BE NAMED AS A DIRECTOR Exhibit 99.7 July 14, 2021 Consent to Reference in Proxy Statement/Prospectus BCTG Acquisition Corp, Inc. (the “Company”) is filing a Registration Statement on Form S-4 (the “Registration Statement”) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”) |
|
| July 16, 2021 |
EX-4.5 2 ea144230ex4-5bctgacq.htm SPECIMEN COMMON STOCK CERTIFICATE OF THE COMBINED ENTITY Exhibit 4.5 NUMBER C- SHARES SEE REVERSE FOR CERTAIN DEFINITIONS CUSIP TANGO THERAPEUTICS, INC. COMMON STOCK THIS CERTIFIES THAT is the owner of fully paid and non-assessable shares of common stock, par value $0.001 per share (the “Common Stock”), of Tango Therapeutics, Inc., a Delaware corporation (the “Com |
|
| July 16, 2021 |
Consent to Reference in Proxy Statement/Prospectus EX-99.4 7 ea144230ex99-4bctgacq.htm CONSENT OF AARON DAVIS TO BE NAMED AS A DIRECTOR Exhibit 99.4 July 14, 2021 Consent to Reference in Proxy Statement/Prospectus BCTG Acquisition Corp, Inc. (the “Company”) is filing a Registration Statement on Form S-4 (the “Registration Statement”) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”). In |
|
| July 16, 2021 |
Consent to Reference in Proxy Statement/Prospectus EX-99.5 8 ea144230ex99-5bctgacq.htm CONSENT OF REID HUBER TO BE NAMED AS A DIRECTOR Exhibit 99.5 July 14, 2021 Consent to Reference in Proxy Statement/Prospectus BCTG Acquisition Corp, Inc. (the “Company”) is filing a Registration Statement on Form S-4 (the “Registration Statement”) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”). In |
|
| July 16, 2021 |
Consent to Reference in Proxy Statement/Prospectus EX-99.3 6 ea144230ex99-3bctgacq.htm CONSENT OF ALEXIS BORISY TO BE NAMED AS A DIRECTOR Exhibit 99.3 July 14, 2021 Consent to Reference in Proxy Statement/Prospectus BCTG Acquisition Corp, Inc. (the “Company”) is filing a Registration Statement on Form S-4 (the “Registration Statement”) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”). |
|
| July 16, 2021 |
Consent to Reference in Proxy Statement/Prospectus EX-99.2 5 ea144230ex99-2bctgacq.htm CONSENT OF BARBARA WEBER TO BE NAMED AS A DIRECTOR Exhibit 99.2 July 14, 2021 Consent to Reference in Proxy Statement/Prospectus BCTG Acquisition Corp, Inc. (the “Company”) is filing a Registration Statement on Form S-4 (the “Registration Statement”) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”). |
|
| July 16, 2021 |
As filed with the U.S. Securities and Exchange Commission on July 15, 2021 As filed with the U.S. Securities and Exchange Commission on July 15, 2021 Registration No. 333-255354 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 3 TO FORM S-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BCTG Acquisition Corp. (Exact name of registrant as specified in its charter) Delaware 6770 85-1195036 (State or Other Jurisdiction of Incorp |
|
| July 15, 2021 |
BCTG Acquisition Corp. 12860 El Camino Real, Suite 300 San Diego, CA 92130 (858) 400-3120 BCTG Acquisition Corp. 12860 El Camino Real, Suite 300 San Diego, CA 92130 (858) 400-3120 July 15, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Irene Paik and Christine Westbrook Re: BCTG Acquisition Corp. Registration Statement on Form S-4 Filed April 20, 2021, as amended Registration No. 333-255354 Dea |
|
| July 6, 2021 |
As filed with the U.S. Securities and Exchange Commission on July 2, 2021 Registration No. 333-255354 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 TO FORM S-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BCTG Acquisition Corp. (Exact name of registrant as specified in its charter) Delaware 6770 85-1195036 (State or Other Jurisdiction of Incorpo |
|
| July 6, 2021 |
Consent of Canaccord Genuity LLC. Exhibit 99.9 Canaccord Genuity LLC 99 High Street Suite 1200 Boston, MA USA 02110 T1: 1.617.371.3900 T2: 1.800.225.6201 cgf.com Consent of Canaccord Genuity LLC Board of Directors BCTG Acquisition Corp. 12860 El Camino Real, Suite 300 San Diego, CA 92130 We hereby consent to the inclusion of our opinion letter, dated April 13, 2021, to the Board of Directors of BCTG Acquisition Corp. (BCTG) as Ann |
|
| July 2, 2021 |
345 Park Avenue New York, NY 10154-1895 Main Fax 212.407.4000 212.407.4990 www.loeb.com July 2, 2021 Via EDGAR Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Attn: Irene Paik Christine Westbrook Re: BCTG Acquisition Corp. Amendment No. 1 to Registration Statement on Form S-4 Filed June 17, 2021 File No. 333-255354 Dear Ms. Paik and M |
|
| June 17, 2021 |
EX-99.1 6 fs42021a1ex99-1bctgacq.htm FORM OF PROXY CARD Exhibit 99.1 PRELIMINARY COPY — SUBJECT TO COMPLETION, DATED [ ] [ ], 2021 PROXY CARD BCTG ACQUISITION CORP. 12860 El Camino Real, Suite 300 San Diego, CA 92130 SPECIAL MEETING OF STOCKHOLDERS THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS OF BCTG ACQUISITION CORP. The undersigned appoints [●] and [●] as proxies, and each of them |
|
| June 17, 2021 |
Consent of Canaccord Genuity LLC. Exhibit 99.9 Canaccord Genuity LLC 99 High Street Suite 1200 Boston, MA USA 02110 T1: 1.617.371.3900 T2: 1.800.225.6201 cgf.com Consent of Canaccord Genuity LLC Board of Directors BCTG Acquisition Corp. 12860 El Camino Real, Suite 300 San Diego, CA 92130 We hereby consent to the inclusion of our opinion letter, dated April 13, 2021, to the Board of Directors of BCTG Acquisition Corp. (BCTG) as Ann |
|
| June 17, 2021 |
345 Park Avenue New York, NY 10154-1895 Main Fax 212.407.4000 212.407.4990 www.loeb.com June 17, 2021 Via EDGAR Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Attn: Irene Paik Christine Westbrook Re: BCTG Acquisition Corp. Registration Statement on Form S-4 Filed April 20, 2021 File No. 333-255354 Dear Ms. Paik and Ms. Westbrook: On |
|
| June 17, 2021 |
Exhibit 10.20 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH ?[***]?. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. LICENSE AGREEMENT This License Agreement (the ?Agreement?) is made and entered into effective as of March 12, 2020 (the ?Effec |
|
| June 17, 2021 |
As filed with the U.S. Securities and Exchange Commission on June 17, 2021 As filed with the U.S. Securities and Exchange Commission on June 17, 2021 Registration No. 333-255354 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BCTG Acquisition Corp. (Exact name of registrant as specified in its charter) Delaware 6770 85-1195036 (State or Other Jurisdiction of Incorp |
|
| June 17, 2021 |
EX-10.19 2 fs42021a1ex10-19bctgacq.htm AMENDED AND RESTATED RESEARCH COLLABORATION AND LICENSE AGREEMENT BETWEEN TANGO THERAPEUTICS, INC. AND GILEAD SCIENCES, INC., DATED AUGUST 17, 2020 Exhibit 10.19 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOUL |
|
| May 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to BCTG ACQUISITION CORP. (Exact name of registrant as sp |
|
| April 26, 2021 |
SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* BCTG Acquisition Corp. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 05492W 103 (CUSIP Number) April 14, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate |
|
| April 20, 2021 |
Consent of Canaccord Genuity LLC. Exhibit 99.9 Canaccord Genuity LLC 99 High Street Suite 1200 Boston, MA USA 02110 T1: 1.617.371.3900 T2: 1.800.225.6201 cgf.com Consent of Canaccord Genuity LLC Board of Directors BCTG Acquisition Corp. 12860 El Camino Real, Suite 300 San Diego, CA 92130 We hereby consent to the inclusion of our opinion letter, dated April 13, 2021, to the Board of Directors of BCTG Acquisition Corp. (BCTG) as Ann |
|
| April 20, 2021 |
Exhibit 10.6 TANGO THERAPEUTICS, INC. 2017 STOCK OPTION AND GRANT PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Tango Therapeutics, Inc. 2017 Stock Option and Grant Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, directors, Consultants and other key persons of Tango Therapeutics, Inc., a Delaware corporation (inc |
|
| April 20, 2021 |
As filed with the U.S. Securities and Exchange Commission on April 19, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BCTG Acquisition Corp. (Exact name of registrant as specified in its charter) Delaware 6770 85-1195036 (State or Other Jurisdiction of Incorporation or Organization) |
|
| April 14, 2021 |
United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 13, 2021 Date of Report (Date of earliest event reported) BCTG Acquisition Corp. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39485 85-1195036 (State or other jurisdiction of incorporation) (Commission Fi |
|
| April 14, 2021 |
Merger Prospectus - CURRENT REPORT United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 13, 2021 Date of Report (Date of earliest event reported) BCTG Acquisition Corp. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39485 85-1195036 (State or other jurisdiction of incorporation) (Commission Fi |
|
| April 14, 2021 |
EX-99.2 5 ea139433ex99-2bctgacq.htm INVESTOR PRESENTATION DATED APRIL 14, 2021 Exhibit 99.2 APRIL 2021 Unmasking vulnerabilities in cancer to deliver the next generation of precision medicines Confidential | 2 Disclaimer This presentation (“Presentation”) is for informational purposes only to assist interested parties in making their own evalua tio n with respect to the proposed business combinati |
|
| April 14, 2021 |
Exhibit 10.1 Confidential Execution Version SUBSCRIPTION AGREEMENT BCTG Acquisition Corp. 12860 El Camino Real, Suite 300 San Diego, CA 92130 Ladies and Gentlemen: In connection with the proposed business combination (the ?Transaction?) between BCTG Acquisition Corp., a Delaware corporation (?BCTG?), and Tango Therapeutics, Inc., a Delaware corporation (?Tango?), pursuant to a merger agreement to |
|
| April 14, 2021 |
Exhibit 99.1 Tango Therapeutics and BCTG Acquisition Corp. Announce Merger Agreement to Create Publicly Listed Precision Medicine Company Focused on the Next Generation of Targeted Cancer Therapies - Leading institutional investors commit $186 million through a common stock private investment in public equity (?PIPE?) led by Boxer Capital - Total proceeds expected to be approximately $353 million, |
|
| April 14, 2021 |
Exhibit 99.2 APRIL 2021 Unmasking vulnerabilities in cancer to deliver the next generation of precision medicines Confidential | 2 Disclaimer This presentation (?Presentation?) is for informational purposes only to assist interested parties in making their own evalua tio n with respect to the proposed business combination (the ?Business Combination?) between BCTG Acquisition Corp. (?BCTG?) and Tan |
|
| April 14, 2021 |
Form of Lock-Up Agreement (incorporated by reference to Exhibit D to Exhibit 2.1). Exhibit 10.1 Confidential Execution Version SUBSCRIPTION AGREEMENT BCTG Acquisition Corp. 12860 El Camino Real, Suite 300 San Diego, CA 92130 Ladies and Gentlemen: In connection with the proposed business combination (the “Transaction”) between BCTG Acquisition Corp., a Delaware corporation (“BCTG”), and Tango Therapeutics, Inc., a Delaware corporation (“Tango”), pursuant to a merger agreement to |
|
| April 14, 2021 |
Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER by and among BCTG ACQUISITION CORP., BCTG MERGER SUB INC., AND TANGO THERAPEUTICS, INC. Dated as of April 13, 2021 Table of Contents Page ARTICLE I THE MERGER 2 Section 1.1 The Merger 2 Section 1.2 Closing 2 Section 1.3 Effective Time 2 Section 1.4 Effects of the Merger 2 Section 1.5 Certificate of Incorporation and Bylaws of the Surviving |
|
| April 14, 2021 |
Exhibit 99.1 Tango Therapeutics and BCTG Acquisition Corp. Announce Merger Agreement to Create Publicly Listed Precision Medicine Company Focused on the Next Generation of Targeted Cancer Therapies - Leading institutional investors commit $186 million through a common stock private investment in public equity (?PIPE?) led by Boxer Capital - Total proceeds expected to be approximately $353 million, |
|
| April 14, 2021 |
EX-2.1 2 ea139433ex2-1bctgacq.htm AGREEMENT AND PLAN OF MERGER, DATED AS OF APRIL 13, 2021 BY AND AMONG BCTG ACQUISITION CORP., BCTG MERGER SUB INC. AND TANGO THERAPEUTICS, INC Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER by and among BCTG ACQUISITION CORP., BCTG MERGER SUB INC., AND TANGO THERAPEUTICS, INC. Dated as of April 13, 2021 Table of Contents Page ARTICLE I THE MERGER 2 Sec |
|
| March 31, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39485 BCTG ACQUISITION CORP. (Exact n |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO §240.13d-2 BCTG Acquisition Corp. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 05492W 103 (CUSIP Number) December 31, 2020 (Date of Event |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* BCTG ACQUISITION CORP. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 05492W103 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| November 13, 2020 |
Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to BCTG ACQUISITION CORP. (Exact Name of Registrant a |
|
| October 7, 2020 |
United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 6, 2020 Date of Report (Date of earliest event reported) BCTG Acquisition Corp. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39485 85-1195036 (State or other jurisdiction of incorporation) (Commission F |
|
| September 14, 2020 |
Financial Statements and Exhibits, Other Events - CURRENT REPORT United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 8, 2020 Date of Report (Date of earliest event reported) BCTG Acquisition Corp. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39485 85-1195036 (State or other jurisdiction of incorporation) (Commission |
|
| September 14, 2020 |
Exhibit 99.1 BCTG ACQUISITION CORP. Report of Independent Registered Public Accounting Firm F-2 Balance Sheet F-3 Notes to Financial Statement F-4 F-1 Report of Independent Registered Public Accounting Firm To the Stockholders and the Board of Directors of BCTG Acquisition Corp. Opinion on the Financial Statement We have audited the accompanying balance sheet of BCTG Acquisition Corp. (the “Compan |
|
| September 9, 2020 |
Exhibit 99.1 BCTG Acquisition Corp., Sponsored by Boxer Capital, LLC, Announces Closing of $166.8 Million Initial Public Offering, Including the Full Exercise of the Underwriter’s Option to Purchase Additional Shares SAN DIEGO— BCTG Acquisition Corp. (Nasdaq: BCTG) (the “Company”) announced today that on September 8, 2020 it closed its initial public offering of 16,675,000 shares of common stock, |
|
| September 9, 2020 |
United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 2, 2020 Date of Report (Date of earliest event reported) BCTG Acquisition Corp. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39485 85-1195036 (State or other jurisdiction of incorporation) (Commission |
|
| September 9, 2020 |
Amended and Restated Certificate of Incorporation of BCTG Acquisition Corp. Exhibit 3.2 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF BCTG ACQUISITION CORP. Pursuant to Section 245 of the Delaware General Corporation Law BCTG Acquisition Corp., a corporation existing under the laws of the State of Delaware, by its Chief Executive Officer, hereby certifies as follows: 1. The name of the corporation is BCTG Acquisition Corp. (hereinafter called the “Corporation”). 2. |
|
| September 9, 2020 |
Exhibit 10.5 September 2, 2020 BCTG Acquisition Corp. 11682 El Camino Real, Suite 320 San Diego, CA 92130 Ladies and Gentlemen: BCTG Acquisition Corp. (the “Company”), a blank check company formed for the purpose of acquiring one or more businesses or entities (a “Business Combination”), intends to register its securities under the Securities Act of 1933, as amended (“Securities Act”), in connecti |
|
| September 9, 2020 |
EX-10.7 10 ea126613ex10-7bctgacq.htm INDEMNITY AGREEMENTS, EACH DATED SEPTEMBER 2, 2020, BY AND BETWEEN THE REGISTRANT AND EACH OF THE REGISTRANT'S OFFICERS AND DIRECTORS Exhibit 10.7 INDEMNITY AGREEMENT THIS INDEMNITY AGREEMENT (this “Agreement”) is made as of September 2, 2020, by and between BCTG Acquisition Corp., a Delaware corporation (the “Company”), and Aaron I. Davis (“Indemnitee”). RECIT |
|
| September 9, 2020 |
Exhibit 10.6 BCTG ACQUISITION CORP. 11682 El Camino Real, Suite 320 San Diego, CA 92130 September 2, 2020 Boxer Capital, LLC 11682 El Camino Real, Suite 320 San Diego, CA 92130 Ladies and Gentlemen: This letter will confirm our agreement that, commencing on the effective date (the “Effective Date”) of the registration statement (the “Registration Statement”) for the initial public offering (the “I |
|
| September 9, 2020 |
Exhibit 10.1 September 2, 2020 BCTG Acquisition Corp. 11682 El Camino Real, Suite 320 San Diego, CA 92130 Re: Initial Public Offering Ladies and Gentlemen: This letter (this “Letter Agreement”) is being delivered to you in accordance with the Underwriting Agreement (the “Underwriting Agreement”) entered into by and among BCTG Acquisition Corp., a Delaware corporation (the “Company”) and SVB Leerin |
|
| September 9, 2020 |
Exhibit 10.2 INVESTMENT MANAGEMENT TRUST AGREEMENT This Agreement is made as of September 2, 2020 by and between BCTG Acquisition Corp. (the “Company”) and Continental Stock Transfer & Trust Company (“Trustee”). WHEREAS, the Company’s registration statements on Form S-1, Nos. 333-240237 and 333-248570 (“Registration Statement”) for its initial public offering of securities (“IPO”) have been declar |
|
| September 9, 2020 |
Exhibit 1.1 14,500,000 Shares of Common Stock BCTG Acquisition Corp. UNDERWRITING AGREEMENT September 2, 2020 SVB LEERINK LLC One Federal Street, 37th Floor Boston, Massachusetts 02110 Ladies and Gentlemen: Introductory: The undersigned, BCTG Acquisition Corp., a Delaware corporation (the “Company”), hereby confirms its agreement with SVB Leerink LLC (“SVB Leerink”) (hereinafter referred to as “yo |
|
| September 9, 2020 |
EX-10.4 7 ea126613ex10-4bctgacq.htm REGISTRATION RIGHTS AGREEMENT, DATED SEPTEMBER 2, 2020, BY AND AMONG THE REGISTRANT, CONTINENTAL STOCK TRANSFER & TRUST COMPANY, LLC, AND THE REGISTRANT'S INITIAL STOCKHOLDERS Exhibit 10.4 REGISTRATION AND STOCKHOLDER RIGHTS AGREEMENT THIS REGISTRATION AND STOCKHOLDER RIGHTS AGREEMENT (this “Agreement”) is entered into as of the 2nd day of September, 2020, by an |
|
| September 9, 2020 |
Exhibit 10.3 STOCK ESCROW AGREEMENT This STOCK ESCROW AGREEMENT, dated as of September 2, 2020 (“Agreement”), by and among BCTG ACQUISITION CORP., a Delaware corporation (“Company”), and the initial shareholders listed on the signature pages hereto (collectively, the “Initial Shareholders”) and CONTINENTAL STOCK TRANSFER & TRUST COMPANY, a New York corporation (“Escrow Agent”). WHEREAS, the Compan |
|
| September 4, 2020 |
BCTG ACQUISITION CORP. 14,500,000 SHARES OF COMMON STOCK PROSPECTUS Filed Pursuant to Rule 424(b)(4) Registration No. 333-240237 $145,000,000 BCTG ACQUISITION CORP. 14,500,000 SHARES OF COMMON STOCK BCTG Acquisition Corp., which we refer to as “we,” “us” or “our company,” is a newly organized blank check company incorporated in Delaware and formed for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalizat |
|
| September 2, 2020 |
As filed with the U.S. Securities and Exchange Commission on September 2, 2020 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 ON FORM S-1/A REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BCTG ACQUISITION CORP. (Exact name of registrant as specified in its charter) Delaware 6770 85-1195036 (State or other jurisdiction of incorp |
|
| September 2, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 BCTG Acquisition Corp. |
|
| August 31, 2020 |
Form of Underwriting Agreement. Exhibit 1.1 12,500,000 Shares of Common Stock BCTG Acquisition Corp. UNDERWRITING AGREEMENT August [ ], 2020 SVB LEERINK LLC One Federal Street, 37th Floor Boston, Massachusetts 02110 Ladies and Gentlemen: Introductory: The undersigned, BCTG Acquisition Corp., a Delaware corporation (the “Company”), hereby confirms its agreement with SVB Leerink LLC (“SVB Leerink”) (hereinafter referred to as “you |
|
| August 31, 2020 |
Form of Subscription Agreement between the Registrant and BCTG Holdings, LLC Exhibit 10.5 September , 2020 BCTG Acquisition Corp. 11682 El Camino Real, Suite 320 San Diego, CA 92130 Ladies and Gentlemen: BCTG Acquisition Corp. (the “Company”), a blank check company formed for the purpose of acquiring one or more businesses or entities (a “Business Combination”), intends to register its securities under the Securities Act of 1933, as amended (“Securities Act”), in connectio |
|
| August 31, 2020 |
Specimen Common Stock Certificate. Exhibit 4.1 NUMBER C- SHARES SEE REVERSE FOR CERTAIN DEFINITIONS CUSIP 05492W 103 BCTG Acquisition Corp. INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE COMMON STOCK This Certifies that is the owner of FULLY PAID AND NON-ASSESSABLE SHARES OF THE PAR VALUE OF $0.0001 EACH OF THE COMMON STOCK OF BCTG Acquisition Corp. (THE “COMPANY”) transferable on the books of the Company in person or by duly |
|
| August 31, 2020 |
Form of Compensation Committee Charter Exhibit 99.2 BCTG ACQUISITION CORP. COMPENSATION COMMITTEE CHARTER OF THE BOARD OF DIRECTORS Purpose of the Committee The purposes of the Compensation Committee (the “Committee”) of the Board of Directors (the “Board”) of BCTG Acquisition Corp. (the “Company”) shall be to oversee the Company’s compensation and employee benefit plans and practices, including its executive, director and other incent |
|
| August 31, 2020 |
Form of Amended and Restated Certificate of Incorporation. Exhibit 3.2 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF BCTG ACQUISITION CORP. Pursuant to Section 245 of the Delaware General Corporation Law BCTG Acquisition Corp., a corporation existing under the laws of the State of Delaware, by its Chief Executive Officer, hereby certifies as follows: 1. The name of the corporation is BCTG Acquisition Corp. (hereinafter called the “Corporation”). 2. |
|
| August 31, 2020 |
Exhibit 14 CODE OF ETHICS 1. Introduction The Board of Directors of BCTG Acquisition Corp. has adopted this code of ethics (this “Code”), which is applicable to all directors, officers and employees, to: ● promote honest and ethical conduct, including the ethical handling of actual or apparent conflicts of interest between personal and professional relationships; ● promote the full, fair, accurate |
|
| August 31, 2020 |
Form of Administrative Support Agreement EX-10.6 13 ea126196ex10-6bctgacq.htm FORM OF ADMINISTRATIVE SUPPORT AGREEMENT Exhibit 10.6 BCTG ACQUISITION CORP. 11682 El Camino Real, Suite 320 San Diego, CA 92130 September , 2020 BCTG HOLDINGS, LLC 11682 El Camino Real, Suite 320 San Diego, CA 92130 Ladies and Gentlemen: This letter will confirm our agreement that, commencing on the effective date (the “Effective Date”) of the registration sta |
|
| August 31, 2020 |
Exhibit 10.1 September [], 2020 BCTG Acquisition Corp. 11682 El Camino Real, Suite 320 San Diego, CA 92130 Re: Initial Public Offering Ladies and Gentlemen: This letter (this “Letter Agreement”) is being delivered to you in accordance with the Underwriting Agreement (the “Underwriting Agreement”) entered into by and among BCTG Acquisition Corp., a Delaware corporation (the “Company”) and SVB Leeri |
|
| August 31, 2020 |
Consent of Jamie G. Christensen Exhibit 99.6 Consent to be Named as a Director Nominee In connection with the filing by BCTG Acquisition Corp. of the Registration Statement on Form S-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board of directors of BCTG Acquisitio |
|
| August 31, 2020 |
Exhibit 99.5 Consent to be Named as a Director Nominee In connection with the filing by BCTG Acquisition Corp. of the Registration Statement on Form S-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board of directors of BCTG Acquisitio |
|
| August 31, 2020 |
Exhibit 10.2 INVESTMENT MANAGEMENT TRUST AGREEMENT This Agreement is made as of September , 2020 by and between BCTG Acquisition Corp. (the “Company”) and Continental Stock Transfer & Trust Company (“Trustee”). WHEREAS, the Company’s registration statement on Form S-1, No. 333-240237 (“Registration Statement”) for its initial public offering of securities (“IPO”) has been declared effective as of |
|
| August 31, 2020 |
Form of Audit Committee Charter Exhibit 99.1 BCTG ACQUISITION CORP. CHARTER OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS Purpose and Policy The primary purpose of the Audit Committee (the “Committee”) shall be to act on behalf of the Board of Directors (the “Board”) of BCTG Acquisition Corp. (the “Company”), in fulfilling the Board’s oversight responsibilities with respect to the Company’s corporate accounting and financial |
|
| August 31, 2020 |
Exhibit 3.1 CERTIFICATE OF INCORPORATION OF BCTG ACQUISITION CORP. THE UNDERSIGNED, for the purpose of incorporating and organizing a corporation under the General Corporation Law of the State of Delaware, does hereby execute this Certificate of Incorporation and does hereby certify as follows: FIRST: The name of the corporation is BCTG Acquisition Corp. (hereinafter called the "Corporation"). SEC |
|
| August 31, 2020 |
Exhibit 10.4 REGISTRATION AND STOCKHOLDER RIGHTS AGREEMENT THIS REGISTRATION AND STOCKHOLDER RIGHTS AGREEMENT (this “Agreement”) is entered into as of the [] day of September, 2020, by and among BCTG Acquisition Corp., a Delaware corporation (the “Company”) and the undersigned parties listed under Investor on the signature page hereto (each, an “Investor” and collectively, the “Investors”). WHEREA |
|
| August 31, 2020 |
Exhibit 99.4 Consent to be Named as a Director Nominee In connection with the filing by BCTG Acquisition Corp. of the Registration Statement on Form S-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board of directors of BCTG Acquisitio |
|
| August 31, 2020 |
Consent of Carole L. Nuechterlein Exhibit 99.3 Consent to be Named as a Director Nominee In connection with the filing by BCTG Acquisition Corp. of the Registration Statement on Form S-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board of directors of BCTG Acquisitio |
|
| August 31, 2020 |
Bylaws of BCTG Acquisition Corp. Exhibit 3.3 BYLAWS OF BCTG Acquisition Corp. - A Delaware Corporation - BY-LAWS OF BCTG ACQUISITION CORP. ARTICLE I OFFICES SECTION 1. Principal Office. The registered office of the corporation shall be located in such place as may be provided from time to time in the Certificate of Incorporation. SECTION 2. Other Offices. The corporation may also have offices at such other places both within and |
